FDA updates certain COVID-19 monoclonal antibody authorizations
 
The Food and Drug Administration Friday updated its emergency use authorizations for two intravenous infusion therapies for outpatients at risk for progressing to severe COVID-19 disease. Specifically, it updated the patient selection criteria and safety summary for the monoclonal antibodies bamlanivimab and etesevimab administered together, and the patient selection criteria for the monoclonal antibodies casirivimab with imdevimab (REGEN-CON) administered together. For details on the changes, see the FDA fact sheets for bamlanivimab and etesevimab and REGEN-COV.
Related News Articles
Headline
  A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
  Headline
  The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
  Headline
  The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
  Headline
  The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
  Headline
  The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
  Headline
  The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
  